Pfizer
PFE
#132
Rank
โ‚ฌ125.37 B
Marketcap
22,05ย โ‚ฌ
Share price
0.51%
Change (1 day)
-3.16%
Change (1 year)

Pfizer Inc., is a global pharmaceutical company headquartered in New York City, New York, United States. It was founded by Charles Pfizer from Ludwigsburg. Pfizer is the second largest pharmaceutical company in the world after Roche, followed by Novartis.

Operating Margin for Pfizer (PFE)

Operating Margin as of December 2025 (TTM): 12.60%

According to Pfizer's latest financial reports and stock price the company's current Operating Margin is 12.60%. At the end of 2024 the company had an Operating Margin of 12.61%.

Operating Margin history for Pfizer from 2001 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
202412.61%609.76%
20231.78%-94.82%
202234.33%14.77%
202129.91%77.04%
202016.89%-38.96%
201927.68%214.38%
20188.80%-62.41%
201723.42%48.13%
201615.81%-13.85%
201518.35%-25.63%
201424.67%-19.01%
201330.47%48.13%
201220.57%9.34%
201118.81%29.43%
201014.53%-32.87%
200921.65%7.86%
200820.07%4.75%
200719.16%-28.85%
200626.93%18.22%
200522.78%-16.73%
200427.36%275.1%
20037.29%-80.03%
200236.53%6.19%
200134.40%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Merck
MRK
31.06% 146.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
18.78% 49.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
16.72% 32.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
37.87% 200.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
29.12% 131.11%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
GlaxoSmithKline
GSK
22.01% 74.68%๐Ÿ‡ฌ๐Ÿ‡ง UK
Amgen
AMGN
22.91% 81.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
18.56% 47.30%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
16.07% 27.54%๐Ÿ‡ฌ๐Ÿ‡ง UK

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.